Weight-loss responses to GLP-1 obesity drugs, and risks of side effects, may be linked to genetic variants, according to a study conducted by DNA-testing service 23AndMe.

Researchers have used saturation genome editing to test every variant in the non coding gene RNU4 2, revealing new pathogenic ...

Dr Aaron Wenger reveals how improvements in long-read sequencing technology is enabling the elucidation of complex disease ...

Accurate prediction of CYP2D6 activity from genotype data is of utmost importance as CYP2D6 pharmacogenetic (PGx) testing is increasingly used to guide drug therapy. However, given the complexity of ...

Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global ...

Variants in GLP‑1 and GIP receptor genes partly determine weight loss and nausea risk on GLP‑1 drugs, signaling a shift from one‑size‑fits‑all treatment.

Inocras and the Broad Institute analyzed 8,000+ TCGA cancer genomes to uncover new drivers and create a harmonized dataset ...

Over the course of five years, researchers sequenced 55,000 genes to produce the first rose pangenome. Coordinated by INRAE ...

Quiver Bioscience ("Quiver"), a discovery technology and therapeutics company advancing programs for the treatment of serious central nervous system (CNS) disorders, today announced a targeted ...

Dax Zey was born on January 1, 2026. It was Herasight’s 11th baby, and Chase and Arthur’s first. He was as healthy as his ...